Matthew Pillar

Matthew Pillar is chief editor at BioProcess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.

Connect with Pillar on LinkedIn at linkedin.com/in/matthewpillar/

ARTICLES BY MATTHEW PILLAR

Maintaining Lab Operations Amid Coronavirus Restrictions
COVID-19 And The Next Chapter In Ansun’s Turnaround Story
Advocates For AI In The Laggard Life Sciences
Big Data: Accelerating EXUMA Biotech In The Race To Rapid CAR-T Therapy
Breaking Down The Science / Finance Language Barrier
The Compounded Risk Of Early-Stage Biopharma Licensing Deals
Mechanistic Action: Genesis Of A Biologics Pipeline?
Precision Medicine In Practice
Securing Biotech Funding When Economies Get Wild
A New Cost Paradigm For CAR Cell Therapies?
The Real Threat To Biopharma Supply Chains: Bioprocessing Materials
ILC Therapeutics’ Interferon Alpha 14 Joins The COVID-19 Fight
Santiago: Leading The Chilean Biotech Revolution
New Podcast: Building Blocks Of The Biopharma Business
Introducing The Business Of Biotech Podcast
Data Intelligence And Biopharma’s COVID-19 Responsibility
Nurturing A Nascent Colorado Biotech Hub
Inside FDA’s AI-Based Established Conditions Pilot
New FDA Guidance For Clinical Trials Disrupted By COVID-19
Virus Exposes Weak Links In The Biopharma Supply Chain
Is Biopharma’s Response To Coronavirus Off The Mark?
Nurturing A Nascent Colorado Biotech Hub
COVID-19: A Case For “Virtual” Biopharma?
The Process Behind The Potential: Therapy For HPV16-Related Malignancies
Update On Advanced Rapid Microbiology Methods In Biopharma